Dalpiciclib in Combination With Exemestane and Trastuzumab Plus Pyrotinib in Early Triple Positive Breast Cancer
This is a phase II open-label, multicenter trial assessing the efficacy of combination regimen"Dalpiciclib plus Exemestane plus trastuzumab plus pyrotinib"in early triple positive breast cancer patients.
Breast Cancer|Estrogen Receptor Positive Tumor|HER2-positive Breast Cancer
DRUG: Trastuzumab Pyrotinib Exemestane Dalpiciclib
pathological complete response (pCR), Assess the rate of pathological complete response (pCR) defined as ypT0-ypTis ypN0 at surgery, at surgery
Serial measures of Ki67, Changes in Ki67 scores from baseline before therapy, 2 weeks after and then at surgery, baseline before therapy, 2 weeks after and at surgery|Objective response, Defined as the number of patients with partial or complete response according to RECIST 1.1, Tumour assessments will be performed by ultrasound and mammography at screening (prior to start of treatment), and before surgery, an expected average of 24 weeks
This is a phase II open-label, multicenter trial. The study assesses the treatment of patients with ER-positive /HER2 positive early breast cancer with neoadjuvant Dalpiciclib in Combination With Exemestane and Trastuzumab plus Pyrotinib. Patients were treated with intravenous trastuzumab (8 mg/kg loading dose followed by 6 mg/kg, Q3W) for six cycles plus oral Dalpiciclib (125 mg QD x 21，Q4W) and Exemestane (25 mg po QD ）and oral pyrotinib (320 mg po QD) for 20 weeks. The primary endpoints was pathological complete response.